<DOC>
	<DOCNO>NCT00164736</DOCNO>
	<brief_summary>This comparative clinical trial among HIV-infected woman infant determine : 1. benefit nutritional supplementation give woman breastfeed 2. benefit safety antiretroviral ( ARV ) medication give either infant mother prevent HIV transmission breastfeed 3. feasibility exclusive breastfeeding follow early , rapid breastfeeding cessation</brief_summary>
	<brief_title>Breastfeeding , Antiretroviral , Nutrition Study</brief_title>
	<detailed_description>This study address complex issue HIV relate maternal morbidity , mortality , postnatal HIV transmission breastfeed wean resource-poor country . Objectives include assessment mortality morbidity among HIV-infected woman ; evaluation intervention reduce HIV transmission infant expose breast milk ; assessment early wean risk-reduction strategy infant HIV-infected mother . The study evaluate following : 1 . The efficacy high-density caloric/micronutrient nutritional supplement give HIV-infected woman breastfeed prevent maternal depletion ( weight loss micronutrient status ) . 2 . The safety efficacy maternal infant antiretroviral regimen , take 6 month breastfeed , reduce infant HIV infection rate 48 week . 3 . The feasibility exclusive breastfeed 6 month follow rapid weaning . Additional study objective evaluate feasibility deliver intervention resource poor setting identify maternal , infant , virologic factor associate HIV transmission breastfeeding .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Recruitment primary eligibility criterion : Age &gt; 14 year . Ability give inform assent consent . Evidence HIV infection , document 2 positive ELISA antibody test ; 1 positive ELISA , 1 Western Blot ; 2 separate concurrent rapid test . Currently pregnant ( single multiple fetus ) . Gestation &lt; 30 week referral 'Call Action ' Program No serious current complication pregnancy . Intention breastfeed . Intention deliver institution study base . Not previously enrol study earlier pregnancy . Other HIV , active serious infection , tuberculosis potentially serious illness . No previous use antiretrovirals include HIVNET 012 regimen . Mother 's CD4 count &gt; 250 cells/uL determine antenatal clinic . Mother 's ALT &lt; 2.5 x ULN ( upper limit normal ) determine antenatal clinic Secondary eligibility criterion treatment assignment : Mother delivers outside institution study base must present infant study site within 36 hour delivery . Mother accepts nevirapine zidovudine+lamivudine 7day regimen infant . Infant birth weight &gt; 2000 g. No severe congenital malformation condition ( ) compatible life . Based clinical assessment , maternal condition would preclude start study intervention .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>breastfeeding</keyword>
	<keyword>mother-to-child-transmission</keyword>
	<keyword>nutrition</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>